This retrospective cohort study conducted at Shizuoka Cancer Center in Japan evaluated the association between best tumor burden change (BTBC) in target lesions and prognosis or toxicity among Japanese patients with stage IV MM who received PD‐1 monotherapy as first‐line treatment. The gene discussed is PDCD1; the disease is Miyoshi myopathy.